108384
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
妊娠期及产后免疫炎症生物标志物与子痫前期不良结局的相关性：一项纵向回顾性分析
Authors Guo X , Tao W, Zhao Q, Qu C, Li X, Sun X, Xu Z
Received 13 June 2025
Accepted for publication 6 September 2025
Published 15 September 2025 Volume 2025:18 Pages 12713—12723
DOI https://doi.org/10.2147/JIR.S544304
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Xinke Guo,1,* Weimin Tao,1,* Qingsong Zhao,2 Cuicui Qu,1 Xiang Li,1 Xiaoru Sun,1 Zhendong Xu1,2
1Department of Intensive Care Unit, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China; 2Department of Anesthesiology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhendong Xu, Department of Intensive Care Unit and Department of Anesthesiology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China, Email btxzd123@126.com Xiaoru Sun, Department of Intensive Care Unit, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China, Email mg1435199@smail.nju.edu.cn
Background: Preeclampsia (PE) is a pregnancy-specific hypertensive disorder linked to systemic inflammation. The systemic immune-inflammation index (SII), calculated from neutrophil, lymphocyte, and platelet counts, has emerged as a novel immune activation marker. Its longitudinal changes in pregnancy and predictive performance for adverse outcomes in PE are not well established.
Methods: This retrospective cohort study included 692 clinical records of women with PE who delivered at Shanghai First Maternity and Infant Hospital between January 2019 and June 2024, representing 685 unique patients, 7 of whom delivered twice. SII, systemic inflammatory response index (SIRI), other inflammatory indices, and biochemical parameters were measured at four time points: the first, second, and third trimesters, and the postpartum. Linear mixed-effects models evaluated longitudinal trends, and random intercepts were used as predictors in logistic regression models assessing adverse pregnancy outcomes. All two-and three-biomarker combinations were evaluated, and DeLong’s test (α = 0.05) was used to compare the area under the Receiver Operating Characteristic (ROC) curves and AUC values of each combination with that of the best single-biomarker model.
Results: Among the 692 records of women with PE, 204 (29.5%) experienced adverse pregnancy outcomes. SII showed an overall increasing trend during pregnancy and demonstrated moderate predictive performance (AUC = 0.666). The combination model including SII, alanine transaminase (ALT), and creatinine (Cr) achieved the highest predictive performance (AUC = 0.712, 95% CI: 0.669− 0.755, P = 0.011), outperforming each single-biomarker.
Conclusion: SII followed an overall increasing trend during pregnancy in patients with PE and was associated with adverse pregnancy outcomes. Combining SII with ALT and Cr improved predictive performance and may be a practical tool for clinical monitoring and early intervention.
Keywords: preeclampsia, systemic immune-inflammation index, adverse pregnancy outcomes, inflammation
1Department of Intensive Care Unit, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China; 2Department of Anesthesiology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhendong Xu, Department of Intensive Care Unit and Department of Anesthesiology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China, Email btxzd123@126.com Xiaoru Sun, Department of Intensive Care Unit, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, People’s Republic of China, Email mg1435199@smail.nju.edu.cn
Background: Preeclampsia (PE) is a pregnancy-specific hypertensive disorder linked to systemic inflammation. The systemic immune-inflammation index (SII), calculated from neutrophil, lymphocyte, and platelet counts, has emerged as a novel immune activation marker. Its longitudinal changes in pregnancy and predictive performance for adverse outcomes in PE are not well established.
Methods: This retrospective cohort study included 692 clinical records of women with PE who delivered at Shanghai First Maternity and Infant Hospital between January 2019 and June 2024, representing 685 unique patients, 7 of whom delivered twice. SII, systemic inflammatory response index (SIRI), other inflammatory indices, and biochemical parameters were measured at four time points: the first, second, and third trimesters, and the postpartum. Linear mixed-effects models evaluated longitudinal trends, and random intercepts were used as predictors in logistic regression models assessing adverse pregnancy outcomes. All two-and three-biomarker combinations were evaluated, and DeLong’s test (α = 0.05) was used to compare the area under the Receiver Operating Characteristic (ROC) curves and AUC values of each combination with that of the best single-biomarker model.
Results: Among the 692 records of women with PE, 204 (29.5%) experienced adverse pregnancy outcomes. SII showed an overall increasing trend during pregnancy and demonstrated moderate predictive performance (AUC = 0.666). The combination model including SII, alanine transaminase (ALT), and creatinine (Cr) achieved the highest predictive performance (AUC = 0.712, 95% CI: 0.669− 0.755, P = 0.011), outperforming each single-biomarker.
Conclusion: SII followed an overall increasing trend during pregnancy in patients with PE and was associated with adverse pregnancy outcomes. Combining SII with ALT and Cr improved predictive performance and may be a practical tool for clinical monitoring and early intervention.
Keywords: preeclampsia, systemic immune-inflammation index, adverse pregnancy outcomes, inflammation